Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 228 Carcinoma, Non-Small-Cell Lung 197 Carcinoma, Renal Cell 129 Neoplasm Metastasis 90 Neoplasms 81 Squamous Cell Carcinoma of Head and Neck 74 Carcinoma, Hepatocellular 73 Colorectal Neoplasms 69 Lung Neoplasms 63 Stomach Neoplasms 50 Pancreatic Neoplasms 49 Hodgkin Disease 40 Carcinoma, Transitional Cell 40 Urinary Bladder Neoplasms 36 Breast Neoplasms 36 Ovarian Neoplasms 34 Head and Neck Neoplasms 34 Triple Negative Breast Neoplasms 31 Small Cell Lung Carcinoma 29 Sarcoma 29 Brain Neoplasms 28 Prostatic Neoplasms 27 Kidney Neoplasms 27 Glioblastoma 27 Recurrence 25 Multiple Myeloma 22 Esophageal Neoplasms 21 Lymphoma 20 Uveal Melanoma 19 Uterine Cervical Neoplasms 19

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡